Share
Market Research Report

ALDOSTERONE SYNTHASE INHIBITORS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Segmentation
  • By Drug TypeSelective Aldosterone Synthase Inhibitors · and Non-Selective CYP11B Inhibitors
  • By DrugOsilodrostat · Lorundrostat · Baxdrostat · Vicadrostat · and Dexfadrostat
  • By IndicationCushing’s Syndrome · Hypertension · and Primary aldosteronism (Conn\\\'s syndrome) · Heart Failure (Heart Failure with Reduced Ejection Fraction (HFrEF), Heart Failure with Preserved Ejection Fraction (HFpEF)) · and Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  • By Stage of DevelopmentPreclinical · Phase I Clinical Trials · Phase II Clinical Trials · Phase III Clinical Trials · and Approved or Marketed
  • By GenderMale · and Female
  • By End UserHospitals · Cardiology Clinics · Nephrology Clinics · Research and Academic Institutes · and Contract Research Organizations (CROs)
  • By GeographyNorth America · Latin America · Europe · Asia Pacific · Middle East & Africa
  • Published In11 Mar 2026
  • Report CodeCMI8275
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026-2033

Market Segmentation

  •  Drug Type Insights (Revenue, USD Mn, 2021 - 2033)

    • Selective Aldosterone Synthase Inhibitors
    • Non-Selective CYP11B Inhibitors

  • Drug Insights (Revenue, USD Mn, 2021 - 2033)

    • Osilodrostat
    • Lorundrostat
    • Baxdrostat
    • Vicadrostat
    • Dexfadrostat

  • Indication Insights (Revenue, USD Mn, 2021 - 2033)

    • Cushing’s Syndrome
    • Hypertension
    • Primary aldosteronism (Conn's syndrome)
    • Heart Failure
    • Heart Failure with Reduced Ejection Fraction (HFrEF)
    • Heart Failure with Preserved Ejection Fraction (HFpEF)
    • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  • Stage of Development Insights (Revenue, USD Mn, 2021 - 2033)

    • Preclinical
    • Phase I Clinical Trials
    • Phase II Clinical Trials
    • Phase III Clinical Trials
    • Approved or Marketed

  • Gender Insights (Revenue, USD Mn, 2021 - 2033)

    • Male
    • Female

  • End User Insights (Revenue, USD Mn, 2021 - 2033)

    • Hospitals
    • Cardiology Clinics
    • Nephrology Clinics
    • Research and Academic Institutes
    • Contract Research Organizations (CROs)

  • Regional Insights (Revenue, USD Mn, 2021 - 2033)

    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa